Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2013

01-03-2013 | Short Communication

Delayed response and survival from NovoTTF-100A in recurrent GBM

Authors: J. Lee Villano, Leena E. Williams, Karriem S. Watson, Nandini Ignatius, Marquess T. Wilson, Tibor Valyi-Nagy, Edward A. Michals, Herbert H. Engelhard

Published in: Medical Oncology | Issue 1/2013

Login to get access

Abstract

We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and has been on device for >6 years. During this time, his magnetic resonance images demonstrated initial growth followed by a slow decrease in enhancement with continued residual disease. Long-term survivors in patients with recurrent GBM are rare, especially in the absence of definitive local treatment such as surgery or radiosurgery. We present the clinical, imaging and pathological findings for this patient in relation to use of the NovoTTF-100A device.
Literature
1.
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.PubMedCrossRef
2.
Valery CA, Seilhean D, Boyer O, Marro B, Hauw JJ, Kemeny JL, et al. Long-term survival after gene therapy for a recurrent glioblastoma. Neurology. 2002;58:1109–12.PubMedCrossRef
3.
Sperduto CM, Chakravarti A, Aldape K, Burger P, Papermaster GB, Sperduto P. Twenty-year survival in glioblastoma: a case report and molecular profile. Int J Radiat Oncol Biol Phys. 2009;75:1162–5.PubMedCrossRef
4.
Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005;23:8863–9.PubMedCrossRef
5.
Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir. 2009;151:1349–58.PubMedCrossRef
6.
Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012.
7.
Louis DN, International Agency for Research on Cancer, World Health Organization, Deutsches Krebsforschungszentrum Heidelberg. WHO classification of tumours of the central nervous system. Lyon Geneva, Switzerland: International Agency for Research on Cancer, Distributed by WHO Press, World Health Organization; 2007. p. 309.
8.
Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65:499–508.PubMedCrossRef
Metadata
Title
Delayed response and survival from NovoTTF-100A in recurrent GBM
Authors
J. Lee Villano
Leena E. Williams
Karriem S. Watson
Nandini Ignatius
Marquess T. Wilson
Tibor Valyi-Nagy
Edward A. Michals
Herbert H. Engelhard
Publication date
01-03-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0338-1

Other articles of this Issue 1/2013

Medical Oncology 1/2013 Go to the issue

Original Paper

Expression of NCAM (CD56), chromogranin A, synaptophysin, c-KIT (CD117) and PDGFRA in normal non-neoplastic skin and basal cell carcinoma: an immunohistochemical study of 66 consecutive cases

Review Article

Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors

Review Article

Melanoma of the female urethra

Original Paper

Clinical features and outcome of patients with HIV-negative multicentric Castleman’s disease treated with combination chemotherapy: a report on 10 patients

Original Paper

Individual predictors of increased serum mesothelin in asbestos-exposed workers

Original Paper

Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits